New Zealand reduces fees, changes abbreviated review rules
This article was originally published in SRA
Executive Summary
New Zealand’s regulatory agency Medsafe has reduced the fees payable for applications for approval of innovative new medicines and for clinical trial approvals1. While the new fees applied from 8 April, the regulatory authority is holding a consultation, and any feedback received by a 22 May deadline will be considered and may result in adjustments.
You may also be interested in...
New Zealand Proposes First Increase In Regulatory Fees Since 2006
New Zealand's medicines regulator plans to increase the fees it charges for various regulatory activities as of June this year. In 2009, the agency had reduced its fees by approximately 12% as its coffers were full and the industry was then told that there would be no changes until the surplus was cleared.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.